Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 22, 2024

EMERYVILLE, Calif., Feb. 8, 2024 /PRNewswire/ — Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2023 financial results on Thursday, February 22, 2024, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Thursday, … Read more

Publication of data from WIL-31 study marks a milestone in improving long-term care for patients with severe von Willebrand disease (VWD)

WIL-31 is the largest prospective prophylaxis study in VWD WIL-31 is the only study in VWD with a prospective on-demand run-in study as an intra-individual comparator wilate® prophylaxis is highly effective at reducing bleeding rates in children and adults with all types of VWD vs prior on-demand treatment LACHEN, Switzerland, Jan. 22, 2024 /PRNewswire/ — Octapharma … Read more

Studies Highlight Both Novel Treatments and Enduring Value of Older Approaches

 Findings suggest “less is more” and “tried and true” may benefit select patients SAN DIEGO, Dec. 10, 2023 /PRNewswire/ — Research findings being presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition highlight new treatment approaches that are enabling patients to live longer or better, judicious uses of older treatment approaches, … Read more

University of Maryland and BioGenCell Announce the Launch of BioGenCell Fifth Chronic Limb-Threatening Ischemia Clinical Trial Site in the United States

BioGenCell has announced the inauguration of the fifth Phase II cell-therapy-based clinical trial site for Chronic Limb-Threatening Ischemia (CLTI) in the United States at the University of Maryland, Baltimore. This initiative is committed to dramatically reducing the incidence of amputations in patients afflicted with severe CLTI. BALTIMORE, Dec. 7, 2023 /PRNewswire/ — BioGenCell, a pioneer … Read more

Skin Cancer and Reconstructive Surgery Center of California Adopts AI-driven Nevisense for early skin cancer detection

STOCKHOLM, Dec. 4, 2023 /PRNewswire/ —SciBase Holding AB (“SciBase”) (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that it will continue its US coast-to-coast momentum with a collaboration agreement with the Skin and Cancer Reconstructive Surgery Center (“SCARS Center”) in California. This partnership will help further introduce Nevisense to a … Read more

Seegene obtient une meilleure note ESG de la part de l’Institut coréen de la gouvernance d’entreprise et du développement durable

La société obtient la note B+ suite aux progrès liés à sa déclaration de gestion des droits de l’homme, à sa boîte d’expédition écologique et à la mise en place d’un comité ESG interne SÉOUL, Corée du Sud, 23 novembre 2023 /PRNewswire/ — Seegene Inc. (KQ096530), une entreprise sud-coréenne de premier plan qui fournit une solution complète … Read more

Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

Updated data from the Phase I trial of RVU120 in relapsed/refractory acute myeloid leukemia (r/r AML) or high-risk myelodysplastic syndromes (HR-MDS) demonstrate clinically relevant benefit in 50% of evaluable patients Preclinical data support RVU120 as a novel agent for the treatment of patients with lower-risk MDS (LR-MDS) and show cytotoxic and differentiating effects on leukemic stem cells … Read more

Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences

DUBLIN, Nov. 1, 2023 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following upcoming investor conferences: Jefferies London Healthcare Conference on Tuesday, November 14, 2023 Fireside chat at 4:30 a.m. PT / 7:30 a.m. ET / 12:30 p.m. GMT 6th Annual Evercore ISI HealthCONx Conference on Tuesday, … Read more

Medical Segment Dominates, Expected to Reach $70.4 Billion by 2030 in the Global Recombinant DNA Technology Market

DUBLIN, Oct. 31, 2023 /PRNewswire/ — The “Recombinant DNA Technology: Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. The global market for Recombinant DNA Technology estimated at US$64.7 Billion in the year 2022, is projected to reach a revised size of US$93.7 Billion by 2030, growing at a CAGR of 4.7% over the analysis period … Read more

First Results with Erdafitinib-Releasing Intravesical Delivery System (TAR-210) Show Early Evidence of Positive Clinical Activity in Patients with Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations

Investigational TAR-210 first-in-human results highlight the potential for local sustained release of erdafitinib with a novel intravesical delivery system  Phase 1 results show a manageable safety profile with limited systemic toxicity, and early complete responses in patients with high-risk and intermediate-risk NMIBC MADRID, Oct. 22, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & … Read more